AMRX (Amneal Pharmaceuticals) PEG Ratio: N/A (As of Jun. 28, 2026)


AMRX Amneal Pharmaceuticals Inc AMRX
63 GF Score
Price $17.24
GF Value $7.57
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Amneal Pharmaceuticals's PE Ratio without NRI is 20.16. Amneal Pharmaceuticals's 5-Year EBITDA growth rate is -5.90%. Therefore, Amneal Pharmaceuticals's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Amneal Pharmaceuticals's PEG Ratio or its related term are showing as below:


During the past 10 years, Amneal Pharmaceuticals's highest PEG Ratio was 33.68. The lowest was 5.79. And the median was 16.36.


AMRX's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.67
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Amneal Pharmaceuticals  (NAS:AMRX) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Amneal Pharmaceuticals PEG Ratio Related Terms


Amneal Pharmaceuticals PEG Ratio Historical Data

* Premium members only.

The historical data trend for Amneal Pharmaceuticals's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals PEG Ratio Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.70 0.00 0.00 0.00 0.00

Amneal Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AMRX vs INDV, KNSA, LQDA: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amneal Pharmaceuticals PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Amneal Pharmaceuticals's PEG Ratio falls into.


AMRX
63GF Score
Amneal Pharmaceuticals Inc AMRX
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amneal Pharmaceuticals PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Amneal Pharmaceuticals's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=20.163742690058/-5.90
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of $17.24 is trading 127.7% above its estimated GF Value™ of $7.57. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for AMRX:

  • PEG Ratio: N/A
  • GF Value™: $7.57 vs. price of $17.24 (127.7% above fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amneal Pharmaceuticals Business Description

Other Exchanges 2DT:Germany
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
63GF Score

Get the complete analysis for AMRX

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.24
Price
$7.57
GF Value